Tesamorelin Clinics in the United States

What Is Tesamorelin?

Tesamorelin is an FDA-approved synthetic GHRH analogue - the only active GH-releasing peptide with full US marketing authorization. It was approved as Egrifta in 2010 for the reduction of excess abdominal fat (lipodystrophy) in HIV-positive patients on antiretroviral therapy.

Beyond its approved indication, tesamorelin is increasingly used off-label at wellness clinics for visceral fat reduction, improved body composition, and cognitive benefits. A 2023 study found it reduced amyloid beta accumulation in the brain, raising interest in its potential for cognitive health.

Tesamorelin stimulates the pituitary to produce more GH in a natural pulsatile pattern. It has a more targeted effect on visceral fat than other GHRH analogues.

Who Considers Tesamorelin?

• Adults with excess visceral abdominal fat seeking physician-supervised reduction
• People interested in growth hormone optimization with an FDA-approved option
• Those pursuing anti-aging or cognitive health protocols
• Patients previously on other GHRH peptides who want a more regulated option

What to Expect at a Consultation

Consultation for tesamorelin includes a health history review, hormone panel, and discussion of your body composition goals. Physicians typically assess visceral fat, metabolic markers, and GH/IGF-1 levels. Treatment is administered via daily subcutaneous injection. Programs vary from 3-12 months depending on goals.